Camptothecin (CPT) directly binds to human heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) and inhibits the hnRNP A1/topoisomerase I interaction.
暂无分享,去创建一个
Kazunori Takada | Yoichi Takakusagi | Yoshihiro Kanai | K. Sakaguchi | F. Sugawara | Yuki Matsumoto | Y. Takakusagi | K. Takakusagi | Senko Tsukuda | Tomoe Kusayanagi | K. Takada | Shinji Kamisuki | Fumio Sugawara | Kengo Sakaguchi | Daisuke Manita | Yuzuru Toba | Yuki Matsumoto | Tomoe Kusayanagi | Kaori Takakusagi | Senko Tsukuda | Y. Kanai | D. Manita | Shinji Kamisuki | Y. Toba | Yoichi Takakusagi | Kaori Takakusagi
[1] R. Hertzberg,et al. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. , 1985, The Journal of biological chemistry.
[2] M. Jafari,et al. Can Drosophila melanogaster represent a model system for the detection of reproductive adverse drug reactions? , 2009, Drug discovery today.
[3] K. Neugebauer,et al. Cotranscriptional coupling of splicing factor recruitment and precursor messenger RNA splicing in mammalian cells , 2006, Nature Structural &Molecular Biology.
[4] F. Zunino,et al. Subcellular localization of the camptothecin analogues, topotecan and gimatecan. , 2004, Biochemical pharmacology.
[5] I. Shalit,et al. Quinolones as enhancers of camptothecin-induced cytotoxic and anti-topoisomerase I effects. , 2008, Biochemical pharmacology.
[6] L. Liu,et al. Involvement of amino acids 361 to 364 of human topoisomerase I in camptothecin resistance and enzyme catalysis. , 1997, Biochemical pharmacology.
[7] M. Diener,et al. Eicosanoid-mediated Cl− secretion induced by the antitumor drug, irinotecan (CPT-11), in the rat colon , 1995, Naunyn-Schmiedeberg's Archives of Pharmacology.
[8] K. Morohashi,et al. Screening of paclitaxel-binding molecules from a library of random peptides displayed on T7 phage particles using paclitaxel-photoimmobilized resin. , 2007, Bioconjugate chemistry.
[9] R. W. Janes,et al. Screening of a library of phage-displayed peptides identifies human bcl-2 as a taxol-binding protein. , 1999, Journal of molecular biology.
[10] K. Sakaguchi,et al. Use of phage display technology for the determination of the targets for small-molecule therapeutics , 2010, Expert opinion on drug discovery.
[11] A. Dunker,et al. Evolution and disorder. , 2011, Current opinion in structural biology.
[12] K. Sakaguchi,et al. Identification of a methotrexate-binding peptide from a T7 phage display screen using a QCM device. , 2008, Bioorganic & medicinal chemistry.
[13] D. Johnson,et al. The Drosophila Hrb87F gene encodes a new member of the A and B hnRNP protein group , 1991, Nucleic Acids Res..
[14] S. Russell,et al. Drosophila melanogaster as a model system for drug discovery and pathway screening. , 2002, Current opinion in pharmacology.
[15] D. Scudiero,et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. , 2002, Cancer research.
[16] C. Nichols,et al. Human Disease Models in Drosophila melanogaster and the Role of the Fly in Therapeutic Drug Discovery , 2011, Pharmacological Reviews.
[17] M. Christman,et al. The Topoisomerase-related Function Gene TRF4 Affects Cellular Sensitivity to the Antitumor Agent Camptothecin* , 1999, The Journal of Biological Chemistry.
[18] K. Sakaguchi,et al. Identification of C10 biotinylated camptothecin (CPT-10-B) binding peptides using T7 phage display screen on a QCM device. , 2007, Bioorganic & medicinal chemistry.
[19] M. Hagiwara,et al. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA , 2007, Nature Chemical Biology.
[20] Yoichi Takakusagi,et al. Camptothecin binds to a synthetic peptide identified by a T7 phage display screen. , 2005, Bioorganic & medicinal chemistry letters.
[21] A. Girstun,et al. SF2/ASF protein binds to the cap region of human topoisomerase I through two RRM domains. , 2005, Biochemical and biophysical research communications.
[22] G. Schwartz,et al. Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells. , 2002, Cancer research.
[23] Ethan Bier,et al. Using Drosophila melanogaster to uncover human disease gene function and potential drug target proteins , 2002, Expert opinion on therapeutic targets.
[24] L. Makowski,et al. Identification of small molecule binding sites within proteins using phage display technology. , 2001, Combinatorial chemistry & high throughput screening.
[25] A. Dunker,et al. Understanding protein non-folding. , 2010, Biochimica et biophysica acta.
[26] A. Girstun,et al. SF2/ASF protein inhibits camptothecin-induced DNA cleavage by human topoisomerase I. , 2002, European journal of biochemistry.
[27] K. Sakaguchi,et al. Identification of trimannoside-recognizing peptide sequences from a T7 phage display screen using a QCM device. , 2009, Bioorganic & medicinal chemistry.
[28] M. Murawska,et al. RRM proteins interacting with the cap region of topoisomerase I. , 2007, Journal of molecular biology.
[29] L. Liu,et al. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. , 1988, Cancer research.
[30] P. Berg,et al. Renaturation of complementary DNA strands mediated by purified mammalian heterogeneous nuclear ribonucleoprotein A1 protein: implications for a mechanism for rapid molecular assembly. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[31] A. McPhail,et al. Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2 , 1966 .
[32] K. Morohashi,et al. Synthesis of a biotinylated camptothecin derivative and determination of the binding sequence by T7 phage display technology. , 2005, Bioorganic & medicinal chemistry letters.
[33] X. F. Dong,et al. Heterogeneous nuclear ribonucleoprotein A1 catalyzes RNA.RNA annealing. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[34] J. Markovits,et al. Protein arginine (N)‐methyl transferase 7 (PRMT7) as a potential target for the sensitization of tumor cells to camptothecins , 2008, FEBS letters.
[35] S. Metallo,et al. Intrinsically disordered proteins are potential drug targets. , 2010, Current opinion in chemical biology.
[36] A. Ikari,et al. Thromboxane A2, released by the anti‐ tumour drug irinotecan, is a novel stimulator of Cl− secretion in isolated rat colon , 1997, The Journal of physiology.
[37] K. Morohashi,et al. A Screening of a Library of T7 Phage-Displayed Peptide Identifies E2F-4 as an Etoposide-Binding Protein , 2011, Molecules.
[38] K. Sakaguchi,et al. A sulfoglycolipid beta-sulfoquinovosyldiacylglycerol (betaSQDG) binds to Met1-Arg95 region of murine DNA polymerase lambda (Mmpol lambda) and inhibits its nuclear transit. , 2010, Protein engineering, design & selection : PEDS.
[39] G. Lazzeri,et al. Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan , 2001, British journal of pharmacology.
[40] Taro Nakamura,et al. NBRP databases: databases of biological resources in Japan , 2009, Nucleic Acids Res..